Jogro
Well-Known Member
The "truth" is that if you had proof that you could cure cancer with hemp oil, you'd be posting the proof instead of resorting to name-calling.boy, you are sure going to feel like an absolute moron when you learn the truth.
I'm not asking for something "crazy" here.
Controlled study is the bare minimum scientific standard use to prove (or disprove) that any therapy is effective. Its used to test the value of every other form of cancer treatment including surgery, conventional chemotherapy, radiation therapy, etc. If cheap hemp oil could actually "cure cancer" it would be trivially easy to prove this is true.
Now, since you apparently don't have any proof, is it really responsible of you to make these sorts of claims?
Not incidentally, "cancer" isn't one disease. There are many different kinds of cancers, and they behave differently and respond to different treatments.
With regards to the image above, basal cell cancers of the skin happen to be the single most common, and single least aggressive cancer known to man. These are barely "cancers" in the commonly used sense of the term since they virtually never spread nor kill anyone. Much of the time, they can be cured with simple scraping (yes SCRAPING. . .not even surgery). In fact, roughly 50% of basal cancers are cured with just simple BIOPSY.
So one picture or case report purporting to show a basal cell cancer treated with hemp oil doesn't really "prove" anything. For example, how do we know the biopsy that diagnosed the basal cell cancer wasn't responsible for the "cure"? At the very least you'd need to look at a large number of these cancers and see how they responded to hemp oil therapy before you could make a credible claim that hemp oil therapy is effective (let alone more effective than other available therapies).
Relevant here, there are already MORE than one available prescription topical medicine that have been proven in multiple clinical studies using significant numbers of patients to cure basal cell cancers with high response rate. Here's some proof:
Note that these just happen to be the first two studies I pulled up on Google; there is actually a whole body of literature on this.Am J Clin Dermatol. 2005;6(3):195-200; discussion 201-2.
Imiquimod: in superficial basal cell carcinoma.
Oldfield V, Keating GM, Perry CM.
Source
Adis International Inc., Yardley, Pennsylvania, USA. [email protected]
Abstract
Imiquimod, available as a 5% cream, is a new topical treatment for adults with superficial basal cell carcinoma (BCC). The exact mechanism of action of imiquimod in superficial BCC is unknown. Imiquimod may act as a toll-like receptor-7 agonist, and is thought to exert its anti-tumor effect via modification of the immune response and stimulation of apoptosis in BCC cells. Topical imiquimod 5% cream effectively increased clinical and histologic clearance of single superficial BCC lesions compared with vehicle in patients enrolled in two large, well designed trials. Patients applied imiquimod five or seven times per week or vehicle for 6 weeks, and the composite clearance rates at 12 weeks post-treatment for the corresponding treatment groups were 75%, 73%, and 2%, respectively. In a trial investigating the long-term efficacy of imiquimod 5% cream following application five times per week for 6 weeks, a clinical clearance rate of 90% was reported at the initial 12-week post-treatment examination. The estimated rate of clinical clearance at the 1-year follow-up visit was 84%. Application site and local skin reactions were the most common adverse events reported by imiquimod recipients. The severity of erythema, erosion, and scabbing/crusting correlated positively with the composite and histologic response rates.
Clin Exp Dermatol. 2004 May;29(3):237-9.
Efficacy of imiquimod 5% cream for basal cell carcinoma in transplant patients.
Vidal D, Alomar A.
Source
Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. [email protected]
Abstract
Imiquimod 5% cream has proven to be effective in superficial and nodular basal cell carcinomas in nonimmunosuppressed patients and treating squamous cell carcinomas in situ in transplant patients. The objective of this open-label study was to determine the efficacy of imiquimod 5% cream in treating basal cell carcinoma in transplant patients. At our unit, four renal transplant patients and one cardiac transplant patient were diagnosed with 10 basal cell carcinomas in 2001. Four tumours were superficial, three nodular and three infiltrative. Five basal cell carcinomas received imiquimod 5% cream at night four times weekly for 6 weeks, without occlusion, and the other five tumours were treated on 5 nights per week for 5 weeks. Biopsies taken 6 weeks after the end of treatment showed no tumour in seven of 10 of the cases. Notably, all four superficial basal cell carcinomas, two of the three of nodular lesions and one of the three of infiltrative cases had completely cleared.
The point is, it shouldn't be particularly difficult to prove that a particular agent is effective in curing cancers. . .particularly skin cancers. . .if it actually is effective. Lacking such proof, the only reasonable stance is to assume that a given therapy isn't effective.